Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration ...
📌 Kaynak
Bu özet Antara News (ID) kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →